Drug intelligence / Profile preview

WIN-901X

Development stage: Phase 2
Lead developer: WhanIn Pharm
Modality: Small Molecules
Administration: Oral

Overview

WIN-901X is an orally available small molecule drug developed by Whanin Pharmaceutical (also referred to as Whan In Pharmaceutical) for the treatment of asthma. It is classified as an antiasthmatic agent. The precise mechanism of action has not been defined or disclosed publicly. Clinical development reached Phase 2 in South Korea, where it was evaluated in a double-blind, randomized, placebo-controlled trial to assess its efficacy, dose-response relationship, and safety profile in patients with asthma[1][2][7]. No further development has been reported since late 2019.

Beyond the preview

Go deeper on WIN-901X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WIN-901X.

Explore the full profile